Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Not yet recruiting · NCT07013851 · Registry updated 2025-06-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer | MMRd/MSI-H Stage II-III Endometrial Cancer | Not yet recruiting | Phase 2 | 2025-06-10 | NCT07013851 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GlaxoSmithKline | 294 |
| Grupo Español de Investigación en Cáncer de Ovario | 4 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Grupo Español de Investigación en Cáncer Ginecológico (GEICO) | Madrid | Spain | 1 |